#USA #Boston #SOPHiA GENETICS #Ross Muken #AI-driven medicine

SOPHiA GENETICS Reports Impressive Financials for 2025 and Future Plans

On January 12, 2026, SOPHiA GENETICS, a prominent entity in AI-powered precision medicine, disclosed its preliminary financial results for both the fourth quarter and the entire year of 2025. The company showed encouraging growth, which included significant revenue milestones and operational accomplishments that suggest a promising outlook for 2026.

2025 Financial Highlights

In a remarkable finish to 2025, SOPHiA GENETICS announced a revenue achievement of at least $21 million for Q4 alone, marking an impressive growth of approximately 20% compared to the same period in the previous year. The company notes another milestone with more than 105,000 analyses conducted using its SOPHiA DDM™ platform in Q4, representing a year-over-year growth of 16%.

When summarizing the full-year performance, SOPHiA GENETICS reports an estimated total revenue of around $77 million, equating to an 18% increase from the prior year. Throughout 2025, the organization executed over 391,000 analyses on its SOPHiA DDM™ system, which set a new record for the company. This impressive performance reflects the company's strategic initiatives and reinforcement of its market presence.

Jurgi Camblong, the current CEO and co-founder, shared insights into the year’s accomplishments, stating, “2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth.” He highlighted that upcoming growth drivers include advancements in their liquid biopsy applications and opportunities in the U.S. market.

2026 Guidance and Expectations

Looking ahead, SOPHiA GENETICS provided guidance for the fiscal year 2026, anticipating a revenue range between $92 million and $94 million. This projection represents a growth rate of approximately 20% to 22% year-over-year. However, the company also cautioned about potential adjusted EBITDA losses estimated between $29 million and $32 million. The company indicated that their operational leverage and strategic initiatives would bolster their financial position moving forward.

Executive Transitions

In addition to financial insights, SOPHiA GENETICS revealed an executive transition plan. Ross Muken, currently the President, has been promoted to Chief Executive Officer, effective July 1, 2026, succeeding Dr. Jurgi Camblong who will take on the role of Executive Chairman. Muken, who has been with the company since February 2021 and has played a pivotal part in driving business performance, expressed excitement over stepping into this new role and continuing collaboration with Camblong.

Dr. Camblong noted, “Having worked closely with Ross for five years, I've seen firsthand his exceptional strategic capabilities and operational leadership. I am confident he is the right person to lead the company through its next phase of growth and significantly expand our global impact.” The transition reflects a long-term succession strategy aimed at preparing SOPHiA GENETICS for a new chapter of expansion and innovation.

Moreover, the executive team will also see Kevin Puylaert take on the role of Chief Sales Officer starting January 2026, marking his over a decade-long contribution to the company. His promotion further emphasizes SOPHiA GENETICS’ dedication to nurturing talent from within and establishing robust leadership amidst evolving market conditions.

Conclusion

SOPHiA GENETICS finished the year on a high note, with strong preliminary financial results that set a solid foundation for expected continued growth in 2026. The strategic appointment of Ross Muken to CEO and the transition of Dr. Camblong to Executive Chairman showcases the company's commitment to its operational strength and long-term vision. With an innovative product lineup and a focused leadership team, SOPHiA GENETICS is poised to make significant strides as it advances the future of precision medicine globally. Follow the company as they prepare for their detailed financial reporting scheduled for March 3, 2026.